Balance Sheet
Cash Flow Statement
Asset Writedowns and ImpairmentCapital ExpendituresCash from Financing ActivitiesCash from Investing ActivitiesCash from OperationsChange in Account PayablesChange in Accured ExpensesChange in Acquisitions & DivestmentsChange in CashChange in InventoryChange in ReceivablesDepreciation & Amortization (CF)Depreciation and DepletionFree Cash FlowGains from Sales and DivestituresNet Cash FlowNet IncomeNon-cash ItemsOther Working Capital ChangesShare-based Compensation
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Puma Biotechnology (PBYI) Free Cash Flow (2017 - 2025)

Historic Free Cash Flow for Puma Biotechnology (PBYI) over the last 9 years, with Q3 2025 value amounting to $9.7 million.

  • Puma Biotechnology's Free Cash Flow fell 1219.82% to $9.7 million in Q3 2025 from the same period last year, while for Sep 2025 it was $42.9 million, marking a year-over-year increase of 2732.4%. This contributed to the annual value of $38.9 million for FY2024, which is 4463.51% up from last year.
  • Puma Biotechnology's Free Cash Flow amounted to $9.7 million in Q3 2025, which was down 1219.82% from $14.1 million recorded in Q2 2025.
  • Puma Biotechnology's 5-year Free Cash Flow high stood at $15.7 million for Q1 2021, and its period low was -$26.9 million during Q1 2022.
  • Its 5-year average for Free Cash Flow is $5.2 million, with a median of $10.3 million in 2022.
  • Per our database at Business Quant, Puma Biotechnology's Free Cash Flow tumbled by 1864864.86% in 2022 and then soared by 129702.09% in 2025.
  • Over the past 5 years, Puma Biotechnology's Free Cash Flow (Quarter) stood at -$5.4 million in 2021, then surged by 370.16% to $14.7 million in 2022, then fell by 29.1% to $10.4 million in 2023, then surged by 49.77% to $15.6 million in 2024, then plummeted by 37.95% to $9.7 million in 2025.
  • Its Free Cash Flow was $9.7 million in Q3 2025, compared to $14.1 million in Q2 2025 and $3.6 million in Q1 2025.